Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Dec:35:1533317519899800.
doi: 10.1177/1533317519899800.

Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment

Shawn Kile  1 , William Au  1 , Carol Parise  2 , Jaideep Sohi  3 , Tracy Yarbrough  3 , Alan Czeszynski  4 , Ken Johnson  4 , Dan Redline  4 , Tammy Donnel  2 , Andrea Hankins  2 , Kimberley Rose  1
Affiliations

Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment

Shawn Kile et al. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec.

Abstract

Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS).

Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed.

Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye.

Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.

Keywords: Alzheimer’s; Aβ; PET; amyloid; disease; intravenous immunoglobulin; mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Change in amyloid positron emission tomography (PET) brain imaging global and regional standard uptake value ratios 3 months after treatment with intravenous immunoglobulin (IVIG).
Figure 2.
Figure 2.
Amyloid positron emission tomography (PET) brain imaging in patients 1 to 5 at baseline and 3 months after treatment with intravenous immunoglobulin (IVIG).
Figure 3.
Figure 3.
Change in retinal amyloid autofluorescent (AF) 3 months after treatment with intravenous immunoglobulin (IVIG).
Figure 4.
Figure 4.
Retinal amyloid autofluorescent (AF) in patients 1 to 5 at baseline and 3 months after treatment with intravenous immunoglobulin (IVIG).
See this image and copyright information in PMC

References

    1. Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26(1):8–16. - PMC - PubMed
    1. Ben Bouallegue F, Mariano-Goulart D, Payoux P; the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimer’s Res Therapy. 2017;9(1):32. - PMC - PubMed
    1. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404–1411. - PubMed
    1. Camus V, Payoux P, Barre L, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39(4):621–631. - PMC - PubMed
    1. Ghosh P, Sorger P, Buelau A, DeClerck J, Schmiedehausen K. Quantitative software evaluation of amyloid brain PET imaging in dementia. White paper. Hoffman Estates (IL): Siemens Medical Solutions USA, Inc. Molecular Imaging. 2012; Report No: A91MI-10381-1T-7600.

Publication types